--- title: 'Industry Daily Summary: What Happened on October 5, 2026' headline: Shionogi buys IntraBio for $2 billion description: CSL will fund development of Alentis’ lixudebart, while Hansa Biopharma adopts Cradle’s protein-design platform. url: https://thebench.bio/news/industry/2026-10-05 topic: industry date: '2026-10-05' covers: - '2026-10-05' date_published: '2026-10-05T12:03:10Z' date_modified: '2026-10-05T12:03:10Z' sources: 3 publisher: The Bench (thebench.bio) --- # Industry Daily Summary: What Happened on October 5, 2026 **Shionogi buys IntraBio for $2 billion** CSL will fund development of Alentis’ lixudebart, while Hansa Biopharma adopts Cradle’s protein-design platform. ## Today in brief Shionogi bought IntraBio for $2 billion. [1] Alentis will receive $355 million upfront from CSL and could earn up to $1.2 billion in commercial milestones for lixudebart. [2] Hansa Biopharma partnered with Cradle to use its protein-design platform across the discovery pipeline. [3] ## CSL and Alentis partner on lixudebart CSL and Alentis Therapeutics formed an exclusive global partnership to develop and commercialize lixudebart, an antibody that targets claudin-1. [2] CSL will fund development, including ongoing and planned studies. [2] Alentis will receive $355 million upfront and could earn up to $1.2 billion in additional commercial milestone payments. [2] If lixudebart reaches the market, CSL would receive 55% of global profits and Alentis 45%. [2] Alentis said an interim analysis of 26 patients in the Phase II RENAL study found improved kidney filtration and lower proteinuria, or protein in the urine, after 24 weeks. [2] Alentis also reported improved liver function after six weeks in its Phase Ib FEGATO study of patients with advanced liver fibrosis. [2] The companies plan Phase II studies in focal segmental glomerulosclerosis and primary sclerosing cholangitis. [2] ## The day in numbers - **$2 billion**: Value of Shionogi’s acquisition of IntraBio. [1] - **$355 million upfront, up to $1.2 billion in milestones**: Potential payments to Alentis under its lixudebart partnership with CSL. [2] - **26 patients, 24 weeks**: RENAL interim analysis time point at which Alentis reported improvements in kidney measures. [2] ## Also published - [PharmaMarketing Summit 2027 to Convene America's Top Pharmaceutical Marketing Executives in California](), pharmaphorum - [Is Pharma Measuring Disengagement Too Late?](), Pharmaceutical Executive - [Thermo Fisher Scientific accelerates market access by prioritizing the right KOLs](), MedTech Dive - [Precision for All: Closing the gap between innovation and impact](), BioPharma Dive - [CSL joins forces with Alentis on claudin candidate](), pharmaphorum ## Sources 1. [Shionogi's diversification continues with $2bn IntraBio buy](), pharmaphorum, 2026-10-05 2. [CSL backs Swiss Alentis’ claudin-1 bet with up to $1.6bn deal](), European Biotechnology, 2026-10-05 3. [Latest News on TechBio Revolution](), MetaphysicalCells, 2026-10-05 --- The Bench wrote this from the reporting cited above, with a language model drafting and editing. [1]: [2]: [3]: